• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Friday, January 27, 2023
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Research reveals how a potentially fatal COVID-19 complication damages lung tissue

Bioengineer by Bioengineer
November 30, 2022
in Health
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Mechanisms involved in the rapid, severe progression of fibrosis in the lung tissues of COVID-19 patients, a potentially fatal complication of the virus that damages and scars the lungs, have been uncovered by researchers led by UTHealth Houston.

Soma S.K. Jyothula, MD

Credit: UTHealth Houston

Mechanisms involved in the rapid, severe progression of fibrosis in the lung tissues of COVID-19 patients, a potentially fatal complication of the virus that damages and scars the lungs, have been uncovered by researchers led by UTHealth Houston.

Until now, little was known about the cellular mechanisms that lead to fulminant lung fibrosis (FLF) in non-resolvable COVID-19. FLF is characterized by the sudden onset and rapid progression of damage to lung tissue, often requiring lung transplantation.

“We believe this is the initial step to understanding post-ARDS fibrosis from COVID-19 and potentially offers us insight into potential therapies for this disease,” said Soma S.K. Jyothula, MD, senior author on the study, and associate professor in the Center for Advanced Cardiopulmonary Therapies and Transplantation at McGovern Medical School at UTHealth Houston.

Of those patients with COVID-19 pneumonia, severe lung disease and acute respiratory distress syndrome (ARDS) has been a primary cause of death since the pandemic began in 2020, Jyothula said.

Evidence of FLF can be seen on average about 15 weeks after symptom onset, according to the study published online by eBio Medicine, part of The Lancet journal family.

Symptoms of FLF of post-COVID-19 ARDS include severely low levels of oxygen in the tissues requiring high amounts of oxygen supplementation, the need for mechanical ventilation, and occasionally support from a machine that oxygenates the patient’s blood outside of the body, then returns it to their system. 

The research revealed a unique fibrotic gene signature in non-resolvable COVID-19 patients; they describe non-resolvable as patients who experienced prolonged pulmonary effects following infection with the virus.

“In some patients with COVID-19, lung injury can progress rapidly to the point that lung transplantation is the only viable option for survival,” said Jyothula, the Graham Distinguished Professor in Pulmonary Medicine at McGovern Medical School.

The study looked at 23 patients (19 male and four female) who had non-resolvable COVID-19 and underwent lung transplantation to treat the disease. They had an average age of 47 and included one patient as young as 16.

All the patients underwent lung transplantation between July 2020 and July 2021.

As a control for the study, researchers utilized discarded donor lung tissue and tissue from patients with pulmonary fibrosis of unknown causes. High resolution images demonstrated evidence of extensive fibrosis in the lungs of non-resolvable COIVD-19 patients.

Lung fibrosis progressed rapidly in the COVID-19 positive patients. Within 119 days from the onset of the condition, lung transplantation was required for the patients’ survival.

Typical presentation of pulmonary fibrosis of unknown causes, which is the most common type of cases, can take years to progress into severe lung disease, according to the research. This publication is the one of the handful of studies currently to describe the molecular details of fibrosis in COVID-19 infected lungs.

The research was funded by The National Institutes of Health, Department of Defense, American Heart Association, American Lung Association, Parker B. Francis Fellowship, and The Center for Clinical Translational Sciences at McGovern Medical School.

Researchers from McGovern Medical School included Andrew Peters, research assistant; Yafen Liang, MD, associate professor; Weizhen Bi, senior research associate; Pooja Shivshankar, assistant professor; Xiaoyi Yuan, PhD, assistant professor; Bindu Akkanti, MD, associate professor; Scott Collum, research program manager; Nancy Wareing, MD/PhD candidate; Bihong Zhao, MD, PhD, associate professor; L. Maximilian Buja, MD; Holger Eltzschig, MD, PhD; and Harry Karmouty-Quintana, PhD, assistant professor.

Buja, Yuan, Eltzschig, and Karmouty-Quintana are also faculty members of The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, and Wareing is a student at the school.

A different study revealed long-term clinical outcomes of COVID-19 patients who underwent lung transplantation.

The research, published in the September issue of Open Forum Infectious Diseases, found that lung transplantation was an acceptable treatment for lung fibrosis due to COVID-19 infection. A total of 13 patients underwent lung transplantation between January 2020 to March 2022 at Memorial Hermann Hospital in Houston. Of those, six were followed for a minimum of six months after surgery and all but one had little to no post-transplant complications and demonstrated excellent long-term outcomes.

One patient died 218 days after surgery from infectious complications.

The study was led by Hana Javaid, MD, and former transplant infectious diseases fellow at McGovern Medical School, and a team of other researchers from the medical school, including Jyothula.



Journal

EBioMedicine

DOI

10.1016/j.ebiom.2022.104351

Article Title

Fulminant lung fibrosis in non-resolvable COVID-19 requiring transplantation

Article Publication Date

11-Nov-2022

Share15Tweet10Share3ShareShareShare2

Related Posts

Reduction in Burnout and Depression Symptoms through Transcendental Meditation

Transcendental Meditation effective in reducing burnout and depression symptoms in physicians

January 27, 2023
Penn Nursing's Amy Lisanti

Science advisory: Advocating for developmental care for infants with complex congenital heart disease

January 26, 2023

Infants born preterm reach similar BMI as their peers born term by adolescence, according to a meta-analysis of 253,810 individuals from 11 countries

January 26, 2023

UK soft drink taxes associated with decreased obesity in girls

January 26, 2023

POPULAR NEWS

  • Jean du Terrail, Senior Machine Learning Scientist at Owkin

    Nature Medicine publishes breakthrough Owkin research on the first ever use of federated learning to train deep learning models on multiple hospitals’ histopathology data

    63 shares
    Share 25 Tweet 16
  • First made-in-Singapore antibody-drug conjugate (ADC) approved to enter clinical trials

    57 shares
    Share 23 Tweet 14
  • Metal-free batteries raise hope for more sustainable and economical grids

    41 shares
    Share 16 Tweet 10
  • One-pot reaction creates versatile building block for bioactive molecules

    37 shares
    Share 15 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

KIMM develops the world’s first electrode design for lithium-ion battery that improves smartphone·laptop battery performance

Outlook for the blue economy

Transcendental Meditation effective in reducing burnout and depression symptoms in physicians

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 42 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In